The impact of time to surgery on oncological outcomes in stage I-III dMMR colon cancer – A nationwide cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
One of the considerations when investigating neoadjuvant interventions is the prolonging of time from diagnosis to curative surgery (i.e. the treatment interval [TI]). The aim of this study was to investigate the association between the length of TI and overall survival and disease-free survival in patients with deficient mismatch repair (dMMR) colon cancer.
Materials and methods
This retrospective propensity score-adjusted study included all patients of ≥18 years of age undergoing elective curative surgery for stage I-III, dMMR colon cancer. Data were extracted from four Danish patient databases. Outcomes were investigated in groups with TIs of ≤14 days versus >14 days. Propensity scores were computed using all demographics, diagnoses and measurements. Matching was done in a 1:1 ratio.
Results
A total of 4130 patients were included in the study with a mean age of 73.8 years and a median follow-up time of 43.9 months. After matching, 2794 patients were included in the analysis of overall survival. No significant difference in overall survival was seen between patients with TIs of ≤14 days versus >14 days (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.81–1.17; p = 0.78). In the analysis of disease-free survival, 1798 patients were included after matching. This showed no significant difference between patients with TIs of ≤14 days versus >14 days (HR, 0.85; 95% CI, 0.69–1.06; p = 0.14).
Conclusion
No associations were found between TI and overall survival and disease-free survival in patients with stage I-III, dMMR colon cancer undergoing elective curative surgery.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 106887 |
| Tidsskrift | European Journal of Surgical Oncology |
| Vol/bind | 49 |
| Udgave nummer | 9 |
| Antal sider | 15 |
| ISSN | 0748-7983 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
The authors are grateful for the support provided by the funding parties including the Innovative Medicines Initiative, the Novo Nordisk Foundation , Region Zealand, and the Danish Ministry of Higher Education and Science . Further, we would like to thank Computerome (The Technical University of Denmark), the European Health Data Evidence Network (EHDEN), and EdenceHealth for their contributions and OHDSI for making available the open-source analytical tool ATLAS. Finally, we acknowledge the Danish Colorectal Cancer Group and the Danish Clinical Quality Program–National Clinical Registries (RKKP) for providing essential data for the project.
Funding Information:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant agreement #806968). Further, the Novo Nordisk Foundation has granted funding with the project title “Personalized medicine infrastructure using the open-source OMOP common data model including an Electronic Health Record interface” (Grant number: NNF21OC0069821). Finally, the Region Zealand and the Danish Ministry of Higher Education and Science granted funding for the project.The authors are grateful for the support provided by the funding parties including the Innovative Medicines Initiative, the Novo Nordisk Foundation, Region Zealand, and the Danish Ministry of Higher Education and Science. Further, we would like to thank Computerome (The Technical University of Denmark), the European Health Data Evidence Network (EHDEN), and EdenceHealth for their contributions and OHDSI for making available the open-source analytical tool ATLAS. Finally, we acknowledge the Danish Colorectal Cancer Group and the Danish Clinical Quality Program–National Clinical Registries (RKKP) for providing essential data for the project.
Funding Information:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant agreement #806968). Further, the Novo Nordisk Foundation has granted funding with the project title “Personalized medicine infrastructure using the open-source OMOP common data model including an Electronic Health Record interface” (Grant number: NNF21OC0069821). Finally, the Region Zealand and the Danish Ministry of Higher Education and Science granted funding for the project.
Publisher Copyright:
© 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
ID: 367703601